Small intestinal bacterial overgrowth
Conditions
Interventions
Trial group:Berberine hydrochloride tablets, 400mg, twice a day for 14d
Control group:Rifaximin tablets, 400mg, twice a day for 14d
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age among 18-65 years old; 2. Gastrointestinal discomforts mainly abdominal pain, distension, constipation, diarrhea for over 6 months and at least one of the symptoms up to moderate or severe degree in the gastrointestinal symptom rating scale (GSRS); 3. Positive lactulose hydrogen methane breath test; 4. Voluntarily join the study and fill in the case report form, hydrogen-methane breath test, colonoscopy and blood biochemical examination; 5. Take drugs according to the required rules with good compliance.
Exclusion criteria
Exclusion criteria: 1. Gastrointestinal organic diseases detected by endoscopy; 2. Patients with severe heart, liver, lung, kidney, blood, endocrine and nervous system diseases, or severe respiratory tract, digestive tract, urinary tract infections or mental disorders; 3. Pregnant or lactating women; 4. Antibiotics and acid suppression drugs for more than 3 days during the past month; 5. Probiotics, laxative, antidiarrhetics, motivation drugs within 2 weeks; 6. Abdominal surgery history; 7. Rifamximin or rifamycin allergy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| negative lactulose hydrogen methane breath test; | — |
Secondary
| Measure | Time frame |
|---|---|
| clinical symptom remission;Improvement of GSRS scale;Changes of fecal flora; | — |
Countries
China
Contacts
Public ContactDuan Liping
Peking University Third Hospital
Outcome results
None listed